Prime Medicine, Inc. announced Phase 1/2 clinical data with PM359 for chronic granulomatous disease (CGD) in the New England Journal of Medicine. Two patients in the trial experienced rapid neutrophil engraftment, restoration of NADPH oxidase activity, and early clinical benefits without safety concerns. This demonstrates the safety and efficacy of Prime Editing and the potential of PM359 as a therapeutic strategy for CGD. The company believes that Prime Editing’s mechanism may be safer for patients than other approaches. Prime Medicine is dedicated to developing gene editing therapies and is progressing a portfolio of therapeutic programs focused on liver, lung, and immunology and oncology.

Read more at GlobeNewswire: Prime Medicine Announces The New England Journal of